Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | CDK8 | P49336 | 2/20 | 0.31 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.31 |
| ▸ | SMO | Q99835 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26798272 | 0.82 | LMNA (0.34) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL10216998 | 0.82 | LMNA (0.34) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL20011130 | 0.80 | TSHR (0.41) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL14670896 | 0.79 | HSD11B1 (0.30) | TSHR | |
| SCHEMBL519126 | 0.77 | — | — | |
| SCHEMBL22813396 | 0.77 | LMNA (0.41) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL3741554 | 0.74 | LMNA (0.39) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL1700728 | 0.74 | LMNA (0.39) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL4021447 | 0.74 | LMNA (0.39) | LMNACHRM2ADRA2ACYP2D6TSHR | |
| SCHEMBL4021446 | 0.74 | LMNA (0.39) | LMNACHRM2ADRA2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | LMNA 762/4885CHRM2 3491/4885ADRA2A 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.